Produktbeschreibung
This Rilvegostomig biosimilar antibody uses the same variable regions as the therapeutic antibody Rilvegostomig, making it ideal for research use. Rilvegostomig is a bispecific antibody that simultaneously targets human PD-1 and TIGIT, two inhibitory immune checkpoint receptors expressed on activated and exhausted T cells as well as subsets of NK cells. By binding both PD-1 and TIGIT, Rilvegostomig is designed to restore antitumor immune responses through dual checkpoint blockade, enhancing T-cell activation, cytokine production, and cytotoxic function while counteracting multiple non-redundant mechanisms of immune suppression within the tumor microenvironment. TIGIT blockade may additionally enhance NK cell activity and reduce inhibitory signaling mediated through interactions with CD155 (PVR) and related ligands. This dual-targeting approach is intended to provide broader immune activation than monospecific checkpoint inhibition alone. This Rilvegostomig biosimilar is well suited for studying PD-1 and TIGIT checkpoint biology, T-cell exhaustion, NK cell regulation, dual checkpoint blockade strategies, and for benchmarking the therapeutic antibodys mechanism of action in pre-clinical experimental systems.
* MwSt. und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
